Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia.

Tropea TF, Mak J, Guo MH, Xie SX, Suh E, Rick J, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Trojanowski JQ, Van Deerlin V, Chen-Plotkin AS.

Ann Neurol. 2019 Jun;85(6):801-811. doi: 10.1002/ana.25486.

PMID:
30973966
2.

Updating Our Definitions of Parkinson's Disease for a Molecular Age.

Chen-Plotkin AS, Zetterberg H.

J Parkinsons Dis. 2018;8(s1):S53-S57. doi: 10.3233/JPD-181487.

3.

AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity.

Amado DA, Rieders JM, Diatta F, Hernandez-Con P, Singer A, Mak JT, Zhang J, Lancaster E, Davidson BL, Chen-Plotkin AS.

Mol Ther. 2019 Feb 6;27(2):465-478. doi: 10.1016/j.ymthe.2018.11.013. Epub 2018 Nov 17.

PMID:
30559071
4.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

5.

Genetic Modifiers in Neurodegeneration.

Jain N, Chen-Plotkin AS.

Curr Genet Med Rep. 2018 Mar;6(1):11-19. doi: 10.1007/s40142-018-0133-1. Epub 2018 Feb 5.

6.

The Post-GWAS Era: From Association to Function.

Gallagher MD, Chen-Plotkin AS.

Am J Hum Genet. 2018 May 3;102(5):717-730. doi: 10.1016/j.ajhg.2018.04.002. Review.

7.

Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.

Shi M, Tang L, Toledo JB, Ginghina C, Wang H, Aro P, Jensen PH, Weintraub D, Chen-Plotkin AS, Irwin DJ, Grossman M, McCluskey L, Elman LB, Wolk DA, Lee EB, Shaw LM, Trojanowski JQ, Zhang J.

Alzheimers Dement. 2018 Aug;14(8):1052-1062. doi: 10.1016/j.jalz.2018.02.015. Epub 2018 Mar 28.

8.

Parkinson disease: Blood transcriptomics for Parkinson disease?

Chen-Plotkin AS.

Nat Rev Neurol. 2018 Jan;14(1):5-6. doi: 10.1038/nrneurol.2017.166. Epub 2017 Dec 1. No abstract available.

9.

APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.

Tropea TF, Xie SX, Rick J, Chahine LM, Dahodwala N, Doshi J, Davatzikos C, Shaw LM, Van Deerlin V, Trojanowski JQ, Weintraub D, Chen-Plotkin AS.

Mov Disord. 2018 Feb;33(2):289-297. doi: 10.1002/mds.27204. Epub 2017 Nov 23.

10.

A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression.

Gallagher MD, Posavi M, Huang P, Unger TL, Berlyand Y, Gruenewald AL, Chesi A, Manduchi E, Wells AD, Grant SFA, Blobel GA, Brown CD, Chen-Plotkin AS.

Am J Hum Genet. 2017 Nov 2;101(5):643-663. doi: 10.1016/j.ajhg.2017.09.004. Epub 2017 Oct 19.

11.

Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Fullard ME, Xie SX, Marek K, Stern M, Jennings D, Siderowf A, Willis AW, Chen-Plotkin AS.

Mov Disord. 2017 Nov;32(11):1636-1640. doi: 10.1002/mds.27127. Epub 2017 Sep 14.

12.

Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease.

Tropea TF, Chen-Plotkin AS.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S15-S18. doi: 10.1016/j.parkreldis.2017.07.021. Epub 2017 Jul 22. Review.

13.

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.

Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS, Hurtig HI, Siderowf AD, Dubroff JG, Weintraub D.

PLoS One. 2017 May 25;12(5):e0177924. doi: 10.1371/journal.pone.0177924. eCollection 2017.

14.

Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype.

Cooper CA, Jain N, Gallagher MD, Weintraub D, Xie SX, Berlyand Y, Espay AJ, Quinn J, Edwards KL, Montine T, Van Deerlin VM, Trojanowski J, Zabetian CP, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Nov 25;4(1):15-25. doi: 10.1002/acn3.371. eCollection 2017 Jan.

15.

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.

Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A; PARS Investigators; Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Mar 29;3(5):346-55. doi: 10.1002/acn3.299. eCollection 2016 May.

16.

Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes.

Busch JI, Unger TL, Jain N, Tyler Skrinak R, Charan RA, Chen-Plotkin AS.

Hum Mol Genet. 2016 Jul 1;25(13):2681-2697. Epub 2016 Apr 28.

17.

Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease.

Roalf DR, Moore TM, Wolk DA, Arnold SE, Mechanic-Hamilton D, Rick J, Kabadi S, Ruparel K, Chen-Plotkin AS, Chahine LM, Dahodwala NA, Duda JE, Weintraub DA, Moberg PJ.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1303-1310. doi: 10.1136/jnnp-2015-312723. Epub 2016 Apr 12.

18.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

19.

An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia.

Berlyand Y, Weintraub D, Xie SX, Mellis IA, Doshi J, Rick J, McBride J, Davatzikos C, Shaw LM, Hurtig H, Trojanowski JQ, Chen-Plotkin AS.

PLoS One. 2016 Jan 26;11(1):e0147319. doi: 10.1371/journal.pone.0147319. eCollection 2016.

20.

Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.

Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS.

Mov Disord. 2015 Oct;30(12):1648-56. doi: 10.1002/mds.26290. Epub 2015 Jul 24.

21.

Unbiased approaches to biomarker discovery in neurodegenerative diseases.

Chen-Plotkin AS.

Neuron. 2014 Nov 5;84(3):594-607. doi: 10.1016/j.neuron.2014.10.031. Epub 2014 Nov 5. Review.

22.

Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype.

Swanson CR, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, Leverenz J, Roberts J, Samii A, Gross RG, Hurtig H, Rick J, Weintraub D, Trojanowski JQ, Zabetian C, Chen-Plotkin AS.

Mov Disord. 2015 May;30(6):805-12. doi: 10.1002/mds.26022. Epub 2014 Sep 16.

23.

TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.

Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, Rohrer JD, Halliday G, Van Broeckhoven C, Seilhean D, Shaw PJ, Frosch MP, Alafuzoff I, Antonell A, Bogdanovic N, Brooks W, Cairns NJ, Cooper-Knock J, Cotman C, Cras P, Cruts M, De Deyn PP, DeCarli C, Dobson-Stone C, Engelborghs S, Fox N, Galasko D, Gearing M, Gijselinck I, Grafman J, Hartikainen P, Hatanpaa KJ, Highley JR, Hodges J, Hulette C, Ince PG, Jin LW, Kirby J, Kofler J, Kril J, Kwok JB, Levey A, Lieberman A, Llado A, Martin JJ, Masliah E, McDermott CJ, McKee A, McLean C, Mead S, Miller CA, Miller J, Munoz DG, Murrell J, Paulson H, Piguet O, Rossor M, Sanchez-Valle R, Sano M, Schneider J, Silbert LC, Spina S, van der Zee J, Van Langenhove T, Warren J, Wharton SB, White CL 3rd, Woltjer RL, Trojanowski JQ, Lee VM, Van Deerlin V, Chen-Plotkin AS.

Acta Neuropathol. 2014 Mar;127(3):407-18. doi: 10.1007/s00401-013-1239-x. Epub 2014 Jan 19.

24.

Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain.

Busch JI, Martinez-Lage M, Ashbridge E, Grossman M, Van Deerlin VM, Hu F, Lee VM, Trojanowski JQ, Chen-Plotkin AS.

Acta Neuropathol Commun. 2013 Jul 11;1:36. doi: 10.1186/2051-5960-1-36.

25.

Development and validation of pedigree classification criteria for frontotemporal lobar degeneration.

Wood EM, Falcone D, Suh E, Irwin DJ, Chen-Plotkin AS, Lee EB, Xie SX, Van Deerlin VM, Grossman M.

JAMA Neurol. 2013 Nov;70(11):1411-7. doi: 10.1001/jamaneurol.2013.3956.

26.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

27.

Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, B Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS.

Ann Neurol. 2013 Jul;74(1):119-27. doi: 10.1002/ana.23872. Epub 2013 Aug 6.

28.

APOE ε4 increases risk for dementia in pure synucleinopathies.

Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP.

JAMA Neurol. 2013 Feb;70(2):223-8. doi: 10.1001/jamaneurol.2013.600.

29.

TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.

Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V, Trojanowski JQ, Lee VM.

J Neurosci. 2012 Aug 15;32(33):11213-27. doi: 10.1523/JNEUROSCI.0521-12.2012.

30.

Genetic influences on cognitive decline in Parkinson's disease.

Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A.

Mov Disord. 2012 Apr;27(4):512-8. doi: 10.1002/mds.24946. Epub 2012 Feb 16.

31.

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ.

Ann Neurol. 2011 Apr;69(4):655-63. doi: 10.1002/ana.22271. Epub 2010 Nov 29.

32.

Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration.

Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, Hu W, Greene R, Wood EM, Bing S, Grossman M, Schellenberg GD, Hatanpaa KJ, Weiner MF, White CL 3rd, Brooks WS, Halliday GM, Kril JJ, Gearing M, Beach TG, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Pickering-Brown SM, Snowden J, van Swieten JC, Heutink P, Seelaar H, Murrell JR, Ghetti B, Spina S, Grafman J, Kaye JA, Woltjer RL, Mesulam M, Bigio E, Lladó A, Miller BL, Alzualde A, Moreno F, Rohrer JD, Mackenzie IR, Feldman HH, Hamilton RL, Cruts M, Engelborghs S, De Deyn PP, Van Broeckhoven C, Bird TD, Cairns NJ, Goate A, Frosch MP, Riederer PF, Bogdanovic N, Lee VM, Trojanowski JQ, Van Deerlin VM.

Arch Neurol. 2011 Apr;68(4):488-97. doi: 10.1001/archneurol.2011.53.

33.

PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.

Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, Elman L, Kalb RG, Trojanowski JQ, Lee VM, Van Deerlin VM, Gitler AD, Bonini NM.

PLoS One. 2011 Mar 29;6(3):e17951. doi: 10.1371/journal.pone.0017951.

34.

Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis.

Vass R, Ashbridge E, Geser F, Hu WT, Grossman M, Clay-Falcone D, Elman L, McCluskey L, Lee VM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS.

Acta Neuropathol. 2011 Mar;121(3):373-80. doi: 10.1007/s00401-010-0782-y. Epub 2010 Nov 23.

35.

Age-correlated gene expression in normal and neurodegenerative human brain tissues.

Cao K, Chen-Plotkin AS, Plotkin JB, Wang LS.

PLoS One. 2010 Sep 29;5(9). pii: e13098. doi: 10.1371/journal.pone.0013098.

36.

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.

Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rüb U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD.

Nature. 2010 Aug 26;466(7310):1069-75. doi: 10.1038/nature09320.

37.

TAR DNA-binding protein 43 in neurodegenerative disease.

Chen-Plotkin AS, Lee VM, Trojanowski JQ.

Nat Rev Neurol. 2010 Apr;6(4):211-20. doi: 10.1038/nrneurol.2010.18. Epub 2010 Mar 16. Review.

38.

Brain progranulin expression in GRN-associated frontotemporal lobar degeneration.

Chen-Plotkin AS, Xiao J, Geser F, Martinez-Lage M, Grossman M, Unger T, Wood EM, Van Deerlin VM, Trojanowski JQ, Lee VM.

Acta Neuropathol. 2010 Jan;119(1):111-22. doi: 10.1007/s00401-009-0576-2. Epub 2009 Aug 2.

39.

TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.

Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu IL, Yang WS, Kalb R, Galasko DR, Montine TJ, Trojanowski JQ, Lee VM, Schellenberg GD, Yu CE.

Lancet Neurol. 2008 May;7(5):409-16. doi: 10.1016/S1474-4422(08)70071-1. Epub 2008 Apr 7.

40.

Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration.

Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, Grossman M, Van Deerlin VM, Trojanowski JQ, Lee VM.

Hum Mol Genet. 2008 May 15;17(10):1349-62. doi: 10.1093/hmg/ddn023. Epub 2008 Jan 25.

41.

Delayed leukoencephalopathy after hypoxic-ischemic injury.

Chen-Plotkin AS, Pau KT, Schmahmann JD.

Arch Neurol. 2008 Jan;65(1):144-5. doi: 10.1001/archneurol.2007.7. No abstract available.

PMID:
18195154
42.

Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.

Chen-Plotkin AS, Yuan W, Anderson C, McCarty Wood E, Hurtig HI, Clark CM, Miller BL, Lee VM, Trojanowski JQ, Grossman M, Van Deerlin VM.

Neurology. 2008 Feb 12;70(7):521-7. Epub 2007 Oct 3.

43.

Demyelinating polyneuropathy and herpes simplex lumbosacral radiculitis in a patient with chronic HIV infection.

Chen-Plotkin AS, Christopoulos KA, Venna N.

AIDS. 2007 Jul 31;21(12):1663-4. No abstract available.

PMID:
17630572
44.

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY.

Neuro Oncol. 2007 Jul;9(3):354-63. Epub 2007 Apr 23.

45.

Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation.

Chen-Plotkin AS, Vossel KA, Samuels MA, Chen MH.

Neurology. 2007 Mar 13;68(11):859-61.

PMID:
17353475
46.

Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease.

Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, DiRocco DP, Farrell LA, Krainc D, Gines S, MacDonald ME, Cha JH.

Neurobiol Dis. 2006 May;22(2):233-41. Epub 2006 Jan 24.

PMID:
16442295
47.

Chromatin immunoprecipitation technique for study of transcriptional dysregulation in intact mouse brain.

Braveman MW, Chen-Plotkin AS, Yohrling GJ, Cha JH.

Methods Mol Biol. 2004;277:261-76.

PMID:
15201461

Supplemental Content

Loading ...
Support Center